Chester County News and Community Website
PHILADELPHIA, PA — Context Therapeutics Inc. (Nasdaq: CNTX) has announced its financial results for the second quarter ended June 30, 2024, along with recent business highlights.
Context Therapeutics Shines Bright: Q2 Successes and Promising Future Read More PHILADELPHIA, PA — Context Therapeutics Inc. (Nasdaq: CNTX) has announced the appointment of Claudio Dansky Ullmann, M.D. as Chief Medical Officer, and Karen Andreas, M.S. as Vice President of Clinical …
Context Therapeutics Appoints New Chief Medical Officer and VP of Clinical Operations Read More PHILADELPHIA, PA — Context Therapeutics Inc. (Nasdaq: CNTX) announced a significant addition to its drug pipeline with the acquisition of CT-95 from Link Immunotherapeutics, Inc. The asset is a mesothelin …
Context Therapeutics Acquires Promising Cancer Treatment Asset Read More PHILADELPHIA, PA — Context Therapeutics Inc. (Nasdaq: CNTX), a pioneering biopharmaceutical company, unveiled its first-quarter financial results for 2024, spotlighting not only solid fiscal performance but also significant strides in …
Context Therapeutics Posts Strong Q1 Financials, Advances Key Cancer Drug Trials Read More PHILADELPHIA, PA — Context Therapeutics Inc. (Nasdaq: CNTX) has received approval from the U.S. Food and Drug Administration (FDA) to commence a Phase 1 clinical trial for CTIM-76, a pioneering …
FDA Clears Context Therapeutics to Begin Trial for Novel Cancer Therapy Read More PHILADELPHIA, PA — Context Therapeutics Inc. (Nasdaq: CNTX), a biopharmaceutical company, announced a private placement agreement expected to generate approximately $100 million in gross proceeds. This influx of capital, before …
Context Therapeutics Secures $100 Million in Private Placement to Fuel Clinical Trials Read More